Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Aug 2009

Zhang Wenyong W, Cortes Jorge E, Yao Hui, Zhang Li, Reddy Neelima G, Jabbour Elias, Kantarjian Hagop M, Jones Dan

Abstract excerpt

PURPOSE: A subset of patients with chronic myelogenous leukemia (CML) do not respond to the tyrosine kinase inhibitor (TKI) imatinib mesylate. Such primary imatinib resistance is distinguished from secondary resistance which reemerges after attainment of cytogenetic remission. PATIENTS AND METHODS: We studied gene expression patterns in total WBCs using a panel of 21 genes previously implicated in TKI handling,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Blast Crisis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genes, abl

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Share to Probability

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 19506164
DOI: 10.1200/JCO.2008.19.4076
PMCID: PMC2799062

Genes

ABL1
PTGS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.PMID 19506164Read ↗

A Single-Cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid LeukemiaSemantic proximity Read ↗

A Single-cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach.Semantic proximity Read ↗

Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patientsSemantic proximity Read ↗

Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitorsSemantic proximity Read ↗

Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukaemia.Semantic proximity Read ↗

Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.Semantic proximity Read ↗

Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylateSemantic proximity Read ↗

Pharmacogenomic Analysis of Cytogenetic Response in Chronic Myeloid Leukemia Patients Treated with ImatinibSemantic proximity Read ↗

Resistance to imatinib in chronic myelogenous leukemia: mechanisms and clinical implications.Semantic proximity Read ↗

A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinibSemantic proximity Read ↗

High expression of COX-2 and MDR1 implicate resistance development to imatinib therapy in chronic myeloid leukemia patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.